CEO, Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada; International Working Group for Antibody Validation (IWGAV) member
Aled Edwards is the founding CEO of the Structural Genomics Consortium (SGC), an international public-private partnership that generates open-sourceresearch tools to support basic science and drug discovery. With 300 scientists within its laboratories in Campinas, Chapel Hill, Frankfurt, Oxford, Stockholm, and Toronto, the SGC has contributed ~15% of all the available structural information for human proteins in the public domain, and has generated chemical probes and validated antibodies that have helped identify new targets for cancer drug discovery. Al was also the founder of Affinium Pharmaceuticals, which was purchased by Debiopharm for its antibiotic program, as well as the Structure-guided Drug Discovery Coalition, a drug discovery partnership currently supported by the Gates Foundation. He is an advisor to Welcome and to a number of governments on Open Science. Al did his undergraduate and graduate work at McGill University and his postdoctoral work at Stanford University with Roger Kornberg, where he initiated the structural biology of RNA polymerase II. He is currently on faculty at the University of Toronto, the University of Oxford, and McGill University.